Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

2017 FDA drug approvals

Nature Reviews Drug Discovery volume 17, pages 81–85 (2018)Cite this article

Subjects

A Corrigendum to this article was published on 01 February 2018

This article has been updated

The FDA approved 46 new drugs last year, the highest total in more than two decades.

The agency's Center for Biologics Evaluation and Research (CBER) also granted a number of landmark approvals, including first approvals for a gene therapy product and for two chimeric antigen receptor (CAR) T cell treatments (Table 2).

Table 2 Selected Center for Biologics Evaluation and Research approvals in 2017
Full size table

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

Rent or Buy

All prices are NET prices.

Figure 1: Novel FDA approvals since 1993.
Figure 2: 2017's potential blockbuster approvals.
Figure 3: CDER approval trends over time.
Figure 4: CDER approvals by therapeutic area in 2017.

Change history

  • 01 February 2018

    Semaglutide is the sixth GLP1 agonist to receive FDA approval, not the fifth as originally noted. This correction has been made in the print and online versions.

Authors
  1. Asher Mullard
    View author publications

    You can also search for this author in PubMed Google Scholar

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mullard, A. 2017 FDA drug approvals. Nat Rev Drug Discov 17, 81–85 (2018). https://doi.org/10.1038/nrd.2018.4

Download citation

Further reading

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing